Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523
December 01 2021 - 7:02AM
Diffusion Pharmaceuticals Inc. (NASDAQ:
DFFN) (“Diffusion” or the “Company”), a biopharmaceutical
company developing novel therapies that enhance the body’s ability
to deliver oxygen to areas where it is needed most, today announced
that it has been granted United States Patent No. 11,185,523, “Use
of Bipolar Trans Carotenoids With Chemotherapy and Radiotherapy for
Treatment of Cancer,” by the United States Patent and Trademark
Office. This patent includes new claims related to methods of
treating cancerous tumors by administering the Company’s lead
product candidate, trans sodium crocetinate (“TSC”), in combination
with radiation therapy and chemotherapy.
"We believe the issuance of this patent
represents another important step in our development of TSC and
provides us with additional intellectual property protection to
support the design and execution of our recently announced clinical
program to support the use of intravenously administered TSC as a
treatment for hypoxic solid tumors," said Robert J. Cobuzzi, Jr.,
Ph.D., President and Chief Executive Office of Diffusion.
About Diffusion Pharmaceuticals
Inc.
Diffusion Pharmaceuticals Inc. is a
biopharmaceutical company developing novel therapies that enhance
the body’s ability to deliver oxygen to areas where it is needed
most. Diffusion’s lead product candidate, TSC, is being developed
to enhance the diffusion of oxygen to tissues with low oxygen
levels, also known as hypoxia, a serious complication of many of
medicine’s most intractable and difficult-to-treat conditions,
including hypoxic solid tumors. In November 2021, based on the
preclinical and clinical data accumulated to date and the
significant unmet medical need, Diffusion announced that its
near-term focus will be the design and execution of a clinical
program to support the use of intravenously administered TSC as a
treatment for hypoxic solid tumors. For more information, please
visit us at www.diffusionpharma.com.
Forward-Looking Statements
This press release includes express and implied
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including
regarding the Company’s near-term strategic priorities and the
potential therapeutic value of TSC. The Company may, in some cases,
use terms such as “believes,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should,” “approximately,” or other words that convey uncertainty
of future events or outcomes to identify these forward-looking
statements. Although the Company believes that it has a reasonable
basis for each forward-looking statement contained herein,
forward-looking statements by their nature involve risks and
uncertainties, known and unknown, many of which are beyond the
Company’s control and, as a result, the Company’s actual results
could differ materially from those expressed or implied in any
forward-looking statement. Particular risk and uncertainties
include, among other things, those related to: the Company’s
ability to design, initiate, enroll, execute, and complete its
planned studies evaluating TSC; the likelihood and timing of
regulatory approval of TSC, if any, for the treatment of solid
tumors complicated by hypoxia or any other indication, or the
nature of any feedback the Company may receive from the U.S. Food
and Drug Administration or other regulatory bodies; the impact of
supply chain and other supplier issues on the Company’s clinical
development program and associated timelines; the Company’s ability
to protect and expand its intellectual property portfolio; the
Company’s ability to maintain compliance with the continued listing
standards of Nasdaq; general economic, political, business,
industry, and market conditions, including the ongoing COVID-19
pandemic; and the other factors discussed under the heading “Risk
Factors” in the Company’s filings most recent Annual Report on Form
10-K and other filings with the U.S. Securities and Exchange
Commission. Any forward-looking statements in this press release
speak only as of the date hereof (or such earlier date as may be
identified) and, except as required by applicable law, rule, or
regulation, the Company undertakes no obligation to update any such
statements after the date hereof.
Contacts:Tiberend Strategic
Advisors, Inc. Maureen McEnroe, CFA/ Lisa
Shermmcenroe@tiberend.com/ lsher@tiberend.com
Media Contact:Kate BarretteRooneyPartners
Kbarrette@rooneypartners.com
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From Sep 2023 to Sep 2024